

Citations and Reference Literature: Copper

Citations

1. Bonham M, O'Connor JM, Hannigan BM, Strain JJ. The immune system as a physiological indicator of marginal copper status? *Br J Nutr* 2002;87:393-403.
2. O'Donohue J, Reid M, Varghese A et al. A case of adult chronic copper self-intoxication resulting in cirrhosis. *Eur J Med Res* 1999;4:252.
3. Malkiel S, Har-el R, Schwalb H et al. Interaction between allopurinol and copper: possible role in myocardial protection. *Free Radic Res Commun* 1993;18:7-15.
4. Lapenna D, de Gioia S, Ciofani G, Cuccurullo F. Antioxidant activity of allopurinol on copper-catalysed human lipoprotein oxidation. *FEBS Lett* 1997;409:265-268.
5. Tompsett SL. Factors influencing the absorption of iron and copper from the alimentary tract. *Biochem J* 1940;34:961-969.
6. Roe DA. *Diet and Drug Interactions*. New York: Van Nostrand Reinhold; 1989.
7. Van Kalmthout PM, Engels LG, Bakker HH, Burghouts JT. Severe copper deficiency due to excessive use of an antacid combined with pyloric stenosis. *Dig Dis Sci* 1982;27:859-861.
8. Conditioned copper deficiency due to antacids. *Nutr Rev* 1984;42:319-321.
9. Solecki TJ, Aviv A, Bogden JD. Effect of a chelating drug on balance and tissue distribution of four essential metals. *Toxicology* 1984;31:207-216.
10. Naveh Y, Weis P, Chung HR, Bogden JD. Effect of cimetidine on tissue distribution of some trace elements and minerals in the rat. *J Nutr* 1987;117:1576-1587.
11. Lambat Z, Limson JL, Daya S. Cimetidine: antioxidant and metal-binding properties. *J Pharm Pharmacol* 2002;54:1681-1686.
12. Kara M, Hasinoff BB, McKay DW, Campbell NR. Clinical and chemical interactions between iron preparations and ciprofloxacin. *Br J Clin Pharmacol* 1991;31:257-261.
13. Wallis SC, Gahan LR, Charles BG et al. Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin: synthesis, X-ray structural characterization, and potentiometric study. *J Inorg Biochem* 1996;62:1-16.
14. Rizk M, Belal F, Ibrahim F et al. Derivative spectrophotometric analysis of 4-quinolone antibacterials in formulations and spiked biological fluids by their Cu(II) complexes. *J AOAC Int* 2001;84:368-375.
15. Powanda MC, Blackburn BS, Bostian KA et al. Clofibrate-induced alterations in zinc, iron and copper metabolism. *Biochem Pharmacol* 1978;27:125-127.
16. Klevay LM. Clofibrate hypocholesterolemia associated with increased hepatic copper. *Drug Nutr Interact* 1983;2:131-137.
17. Fields M, Lewis CG, Lure MD. Copper deficiency in rats: the effect of clofibrate. *J Am Coll Nutr* 1992;11:399-404.
18. Eagon PK, Teepe AG, Elm MS et al. Hepatic hyperplasia and cancer in rats: alterations in copper metabolism. *Carcinogenesis* 1999;20:1091-1096.
19. Horwitt MK, Harvey CC, Dahm CH Jr. Relationship between levels of blood lipids, vitamins C, A, and E, serum copper compounds, and urinary excretions of tryptophan metabolites in women taking oral contraceptive therapy. *Am J Clin Nutr* 1975;28:403-412.
20. Dorea JG, Ferraz E, Queiroz EF. [Effects of anovulatory steroids on serum levels of zinc and copper]. *Arch Latinoam Nutr* 1982;32:101-110.
21. Mehta SW, Eikum R. Effect of estrogen on serum and tissue levels of copper and zinc. *Adv Exp Med Biol* 1989;258:155-162.
22. Newhouse IJ, Clement DB, Lai C. Effects of iron supplementation and discontinuation on serum copper, zinc, calcium, and magnesium levels in women. *Med Sci Sports Exerc* 1993;25:562-571.
23. Liukko P, Erkkola R, Pakarinen P et al. Trace elements during 2 years' oral contraception with low-estrogen preparations. *Gynecol Obstet Invest* 1988;25:113-117.
24. Johnson PE, Milne DB, Lykken GI. Effects of age and sex on copper absorption, biological half-life, and status in humans. *Am J Clin Nutr* 1992;56:917-925.
25. Berg G, Kohlmeier L, Brenner H. Effect of oral contraceptive progestins on serum copper concentration. *Eur J Clin Nutr* 1998;52:711-715.
26. Bureau I, Anderson RA, Arnaud J et al. Trace mineral status in post menopausal women: impact of hormonal replacement therapy. *J Trace Elem Med Biol* 2002;16:9-13.
27. Salonen JT, Salonen R, Korpela H et al. Serum copper and the risk of acute myocardial infarction: a prospective population study in men in eastern Finland. *Am J Epidemiol* 1991;134:268-276.
28. Reunanen A, Knekt P, Marniemi J et al. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. *Eur J Clin Nutr* 1996;50:431-437.
29. Cole A, May PM, Williams DR. Metal binding by pharmaceuticals. Part 1. Copper(II) and zinc(II) interactions following ethambutol administration. *Agents Actions* 1981;11:296-305.

Citations and Reference Literature: Copper

30. Kozak SF, Inderlied CB, Hsu HY et al. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. *Diagn Microbiol Infect Dis* 1998;30:83-87.
31. Kaimbo WK, Bifuko ZA, Longo MB et al. Color vision in 42 Congolese patients with tuberculosis receiving ethambutol treatment. *Bull Soc Belge Ophtalmol* 2002;57-61.
32. Kozlowski H, Kowalik-Jankowska T, Anouar A et al. Famotidine, the new antiulcero-genic agent, a potent ligand for metal ions. *J Inorg Biochem* 1992;48:233-240.
33. Sorenson JR. Copper chelates as possible active forms of the antiarthritic agents. *J Med Chem* 1976;19:135-148.
34. Brumas V, Brumas B, Berthon G. Copper(II) interactions with nonsteroidal antiinflammatory agents. I. Salicylic acid and acetylsalicylic acid. *J Inorg Biochem* 1995;57:191-207.
35. Miche H, Brumas V, Berthon G. Copper(II) interactions with nonsteroidal antiinflammatory agents. II. Anthranilic acid as a potential OH-inactivating ligand. *J Inorg Biochem* 1997;68:27-38.
36. Gaubert S, Bouchaut M, Brumas V, Berthon G. Copper-ligand interactions and the physiological free radical processes. Part 3. Influence of histidine, salicylic acid and anthranilic acid on copper-driven Fenton chemistry in vitro. *Free Radic Res* 2000;32:451-461.
37. Kishore V. Effects of copper aspirinate and aspirin on tissue copper, zinc, and iron concentrations following chronic oral treatment in the adjuvant arthritic rat. *Biol Trace Elem Res* 1990;25:123-135.
38. Schilsky ML. Wilson disease: genetic basis of copper toxicity and natural history. *Semin Liver Dis* 1996;16:83-95.
39. Subramanian I, Vanek ZF, Bronstein JM. Diagnosis and treatment of Wilson's disease. *Curr Neurol Neurosci Rep* 2002;2:317-323.
40. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. *Exp Biol Med* (Maywood) 2001;226:665-673.
41. Cox C, Teknos TN, Barrios M et al. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. *Laryngoscope* 2001;111:696-701.
42. Kodama H, Murata Y, Iitsuka T, Abe T. Metabolism of administered triethylene tetramine dihydrochloride in humans. *Life Sci* 1997;61:899-907.
43. Klein D, Lichtmanegger J, Heinzmann U, Summer KH. Dissolution of copper-rich granules in hepatic lysosomes by D-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats. *J Hepatol* 2000;32:193-201.
44. Tanabe R. [Disposition behavior and absorption mechanism of trientine, an orphan drug for Wilson's disease]. *Hokkaido Igaku Zasshi* 1996;71:217-228.
45. Sorenson JR, Hangarter W. Treatment of rheumatoid and degenerative diseases with copper complexes: a review with emphasis on copper-salicylate. *Inflammation* 1977;2:217-238.
46. Khan MK, Miller MW, Taylor J et al. Radiotherapy and antiangiogenic TM in lung cancer. *Neoplasia* 2002;4:164-170.
47. Pan Q, Kleer CG, van Golen KL et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. *Cancer Res* 2002;62:4854-4859.
48. Brewer GJ, Johnson VD, Dick RD et al. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. *Hepatology* 2000;31:364-370.
49. Hurd RW, Van Rinsvelt HA, Wilder BJ et al. Selenium, zinc, and copper changes with valproic acid: possible relation to drug side effects. *Neurology* 1984;34:1393-1395.
50. Lerman-Sagie T, Statter M, Szabo G, Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. *Clin Neuropharmacol* 1987;10:80-86.
51. Sozuer DT, Barutcu UB, Karakoc Y et al. The effects of antiepileptic drugs on serum zinc and copper levels in children. *J Basic Clin Physiol Pharmacol* 1995;6:265-269.
52. Kurekci AE, Alpay F, Tanindi S et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. *Epilepsia* 1995;36:600-604.
53. Verrotti A, Basciani F, Trotta D et al. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. *Epilepsy Res* 2002;48:71-75.
54. Kaji M, Ito M, Okuno T et al. Serum copper and zinc levels in epileptic children with valproate treatment. *Epilepsia* 1992;33:555-557.
55. Suzuki T, Koizumi J, Moroji T et al. Effects of long-term anticonvulsant therapy on copper, zinc, and magnesium in hair and serum of epileptics. *Biol Psychiatry* 1992;31:571-581.
56. Baum MK, Javier JJ, Mantero-Atienza E et al. Zidovudine-associated adverse reactions in a longitudinal study of asymptomatic HIV-1-infected homosexual males. *J Acquir Immune Defic Syndr* 1991;4:1218-1226.
57. Graham NM, Sorensen D, Odaka N et al. Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS. *J Acquir Immune Defic Syndr* 1991;4:976-980.

Citations and Reference Literature: Copper

58. Allavena C, Dousset B, May T et al. Relationship of trace element, immunological markers, and HIV1 infection progression. *Biol Trace Elem Res* 1995;47:133-138.
59. Lai H, Lai S, Shor-Posner G et al. Plasma zinc, copper, copper:zinc ratio, and survival in a cohort of HIV-1-infected homosexual men. *J Acquir Immune Defic Syndr* 2001;27:56-62.
60. Jimenez-Exposito MJ, Bullo Bonet M, Alonso-Villaverde C et al. [Micronutrients in HIV infection and the relationship with the inflammatory response]. *Med Clin (Barc)* 2002;119:765-769.
61. Gyorffy EJ, Chan H. Copper deficiency and microcytic anemia resulting from prolonged ingestion of over-the-counter zinc. *Am J Gastroenterol* 1992;87:1054-1055.

Reference Literature

- [No author listed.] Cuprimine product information (MSD-U.S.). Whitehouse Station, NJ; Merck & Co. Inc; Rec 7/89, Rev 3/89.
- [No author listed.] Syprine product information (MSD-U.S.) West Point, PA: Merck & Co, Inc; Rec 11/89, Rev 3/89.
- Abdel-Mageed A, Oehme F. A review of biochemical roles, toxicity and interactions of zinc, copper and iron: II: copper. *Vet Hum Toxicol* 1990;32(3):230-234.
- Aggett PJ. An overview of the metabolism of copper. *Eur J Med Res* 1999;4(6):214-216. (Review)
- Aoyogi S, Baker DH. Bioavailability of copper in analytical-grade and feed-grade inorganic copper sources when fed to provide copper at levels below the chicks requirement. *Poult Sci* 1993;72:1075-1083.
- Baker DH, Odle J, Funk MA, et al. Bioavailability of copper in cupric oxide, cuprous oxide and in a copper-lysine complex. *Poult Sci* 1991;70:177-179.
- Baker DH. Cupric oxide should not be used as a copper supplement for either animals or humans. *J Nutr* 1999;129:2278-2279.
- Bedwal RS, Bahuguna A. Zinc, copper and selenium in reproduction. *Experientia* 1994;50(7):626-640. (Review)
- Burkitt MJ. A critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: roles of lipid hydroperoxides, alpha-tocopherol, thiols, and ceruloplasmin. *Arch Biochem Biophys* 2001;394(1):117-135.
- Covington T, ed. Nonprescription drug therapy guiding patient self-care. St Louis: Facts and Comparisons; 1999:467-545.
- Cromwell GL, Stahly TS, Moneque HJ. Effects of source and level of copper on performance and liver copper stores in weanling pigs. *J Anim Sci* 1989;67:2996-3002.
- Dunlap W, James W, Hume D. Anemia and neutropenia caused by copper deficiency. *Ann Int Med* 1974;80:470-476.
- Falchuk KH. Disturbances in trace elements. In: Fauci A, Braunwald E, Isselbacher KJ, et al, eds. *Harrison's principles of internal medicine*. 14 th ed. New York: McGraw-Hill Companies Health Professional Division; 1998:490-491.
- Fields M, Lewis CG, Lure MD. Garlic oil extract ameliorates the severity of copper deficiency. *J Am Coll Nutr* 1992;11(3):334-339.
- Ford ES. Serum copper concentration and coronary heart disease among US adults. *Am J Epidemiol* 2000;151:1182-1188.
- George GN, Pickering IJ, Harris HH, et al. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease. *J Am Chem Soc* 2003;125(7):1704-1705.
- Harris ED. Copper homeostasis: the role of cellular transporters. *Nutr Rev* 2001;59(9):281-285.
- Harvey LJ, Dainty JR, Hollands WJ, et al. Use of mathematical modeling to study copper metabolism in humans. *Am J Clin Nutr* 2005;81(4):807-813.
- Heller RM, Kirchner SG, O'Neill JA Jr, et al. Skeletal changes of copper deficiency in infants receiving prolonged total parenteral nutrition. *J Pediatr* 1978;92(6):947-949.
- Hoffman H, Phyllyk R, Fleming C. Zinc-induced copper deficiency. *Gastroenterology* 1988;94:508-512.
- Holt GA. Food and drug interactions. Chicago: Precept Press;1998.
- Jaanus SD. Ocular side effects of selected systemic drugs. *Optom Clin* 1992;2(4):73-96. (Review)
- Jacob RA, Skala JH, Omaye ST, et al. Effect of varying ascorbic acid intakes on copper absorption and ceruloplasmin levels of young men. *J Nutr* 1987;117:2109-2115.
- Jantsch W, Kulig K, Rumack BH. Massive copper sulfate ingestion resulting in hepatotoxicity. *J Toxicol Clin Toxicol* 1984-85;22(6):585-588.
- Jones AA, DiSilvestro RA, Coleman M, et al. Copper supplementation of adult men: effects on blood copper enzyme activities and indicators of cardiovascular disease risk. *Metabolism* 1997;46:1380-1383.
- Keen CL, Lonnerdal B, Hurley LS. Drug-induced copper deficiency: a model for copper deficiency teratogenicity. *Teratology* 1983;28(1):155-156.
- Kelley DS, Daudu PA, Taylor PC, et al. Effects of low-copper diets on human immune response. *Am J Clin Nutr* 1995;62(2):412-416.
- Klevay LM. Copper in legumes may lower heart disease risk. *Arch Intern Med* 2002;162(15):1780. (Letter)

Citations and Reference Literature: Copper

- Klevay LM, Medeiros DM. Deliberations and evaluations of the approaches, endpoints and paradigms for dietary recommendations about copper. *J Nutr* 1996;126:2419S-2426S.
- Kuzuya T, Amioka K, Nabeshima T. Valproic acid increases biliary copper excretion in the rat. *Epilepsy Res* 2002;51(3):279-285.
- Ledoux DR, Henry PR, Ammerman CB, et al. Estimation of the relative bioavailability of inorganic copper sources for chicks using tissue uptake of copper. *J Anim Sci* 1991;69:215-222.
- Lowe NM, Lowe NM, Fraser WD, et al. Is there a potential therapeutic value of copper and zinc for osteoporosis? *Proc Nutr Soc* 2002;61(2):181-185. (Review)
- Mahabir S, Spitz MR, Barrera SL, et al. Dietary zinc, copper and selenium, and risk of lung cancer. *Int J Cancer* 2006. Epub ahead of print.
- Mason K. A conspectus of research on copper metabolism and requirements of man. *J Nutr* 1979;109(11):1979-2066.
- Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. *J Am Coll Cardiol* 1996;27(3):517-527.
- Medeiros DM, Wildman R. New findings on a unified perspective of copper restriction and cardiomyopathy. *Proc Soc Exp Biol Med* 1997;215:299-313.
- Milne DB. Copper intake and assessment of copper status. *Am J Clin Nutr* 1998;67(5 Suppl):1041S-1045S. (Review)
- Milne DB, Davis CD, Nielsen FH. Low dietary zinc alters indices of copper function and status in postmenopausal women. *Nutrition* 2001;17(9):701-708.
- Milne DB, Johnson PE. Assessment of copper status: effect of age and gender on reference ranges in healthy adults. *Clin Chem* 1993;39(5):883-887.
- National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press; 1989.
- Pandit A, Bavdekar A, Bhav S. Wilson's disease. *Indian J Pediatr* 2002;69(9):785-791. (Review)
- Perry AR, Pagliuca A, Fitzsimons EJ, et al. Acquired sideroblastic anaemia induced by a copper-chelating agent. *Int J Hematol* 1996;64(1):69-72.
- Powanda MC, Blackburn BS, Bostian KA, et al. Clofibrate-induced alterations in zinc, iron and copper metabolism. *Biochem Pharmacol* 1978;27(1):125-127.
- Robinson C, Weigly E. Basic nutrition and diet therapy. New York: MacMillan;1984.
- Roe DA. Diet and drug interactions. New York: Van Nostrand Reinhold;1989.
- Roe DA. Drug-induced nutritional deficiencies. 2nd ed. Westport, CT: Avi Publishing;1985.
- Roe DA. Risk factors in drug-induced nutritional deficiencies. In: Roe DA, Campbell T, eds. *Drugs and nutrients: the interactive effects*. New York: Marcel Dekker;1984:505-523.
- Rossi L, Marchese E, Lombardo MF, et al. Increased susceptibility of copper-deficient neuroblastoma cells to oxidative stress-mediated apoptosis. *Free Radic Biol Med* 2001;30(10):1177-1187.
- Saltman PD, Strause LG. The role of trace minerals in osteoporosis. *J Am Coll Nutr* 1993;12(4):384-389.
- Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. *Am J Clin Nutr* 1995;61(Suppl): 62S-64S.
- Sandstead H. Trace element interactions. *J Lab Clin Med* 1981;98(4):457-462.
- Shepherd RG, Baughn C, Cantrall ML, et al. Structure-activity studies leading to ethambutol, a new type of antituberculous compound. *Ann N Y Acad Sci* 1966;135(2):686-710.
- Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. *Neurology* 2002;59(8):1153-1161.
- Strain JJ. A reassessment of diet and osteoporosis: possible role for copper. *Med Hypotheses* 1988;27(4):333-338.
- Strause L, Saltman P, Smith KT, et al. Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. *J Nutr* 1994;124(7):1060-1064.
- Suzuki KT, Ogura Y. [Biological regulation of copper and selective removal of copper: therapy for Wilson disease and its molecular mechanism.] *Yakugaku Zasshi* 2000;120(10):899-908. [Japanese] (Review)
- Suzuki KT, Someya A, Komada Y, et al. Roles of metallothionein in copper homeostasis: responses to Cu-deficient diets in mice. *J Inorg Biochem* 2002;88(2):173-182.
- Threlkeld DS, ed. Miscellaneous products, penicillamine. In: *Facts and comparisons drug information*. St Louis: Facts and Comparisons; 1996.
- Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. *Am Fam Physician* 1991;44(5):1651-1658. (Review)
- Turnland J. Copper nutriture, bioavailability, and the influence of dietary factors. *J Am Diet Assoc* 1988;88:303-308.
- Turnlund JR, Jacob RA, Keen CL, et al. Long-term high copper intake: effects on indexes of copper status, antioxidant status, and immune function in young men. *Am J Clin Nutr* 2004;79(6):1037-1044.

Citations and Reference Literature: Copper

- Turnlund JR, Keyes WR, Kim SK, et al. Long-term high copper intake: effects on copper absorption, retention, and homeostasis in men. *Am J Clin Nutr* 2005;81(4):822-828.
- Turnlund JR, Scott KC, Peiffer GL, et al. Copper status of young men consuming a low-copper diet. *Am J Clin Nutr* 1997;65(1):72-78.
- Vanchieri C. Cutting copper curbs angiogenesis, studies show. *J Natl Cancer Inst* 2000;92(15):1202-1203.
- Werbach MR. Foundations of nutritional medicine. Tarzana, CA: Third Line Press;1997. (Review)
- Youssef A, Wood B, Baron DN. Serum copper: a marker of disease activity in rheumatoid arthritis. *J Clin Pathol* 1983;36:14-17.
61. Folkers K, Choe JY, Combs AB. Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of Adriamycin in the rat. *Proc Natl Acad Sci U S A* 1978;75:5178-5180.
62. Choe JY, Combs AB, Saji S, Folkers K. Study of the combined and separate administration of doxorubicin and coenzyme Q10 on mouse cardiac enzymes. *Res Commun Chem Pathol Pharmacol* 1979;24:595-598.
63. Choe JY, Combs AB, Folkers K. Prevention by coenzyme Q10 of the electrocardiographic changes induced by Adriamycin in rats. *Res Commun Chem Pathol Pharmacol* 1979;23:199-202.
64. Lubawy WC, Dallam RA, Hurley LH. Protection against anthracycline-induced toxicity in mice by coenzyme Q10. *J Natl Cancer Inst* 1980;64:105-109.
65. Shaeffer J, El-Mahdi AM, Nichols RK. Coenzyme Q10 and Adriamycin toxicity in mice. *Res Commun Chem Pathol Pharmacol* 1980;29:309-315.
66. Usui T, Ishikura H, Izumi Y et al. Possible prevention from the progression of cardiotoxicity in Adriamycin-treated rabbits by coenzyme Q10. *Toxicol Lett* 1982;12:75-82.
67. Shinozawa S, Kawasaki H, Gomita Y. [Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on Adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice]. *Gan To Kagaku Ryoho* 1996;23:93-98.
68. Shinozawa S, Gomita Y, Araki Y. Tissue concentration of doxorubicin (Adriamycin) in mouse pretreated with alpha-tocopherol or coenzyme Q10. *Acta Med Okayama* 1991;45:195-199.
69. Neri B, Neri GC, Bandinelli M. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. *Oncology* 1988;45:242-246.
70. Ronca-Testoni S, Zucchi R, Ronca F, Bertelli A. Effect of carnitine and coenzyme Q10 on the calcium uptake in heart sarcoplasmic reticulum of rats treated with anthracyclines. *Drugs Exp Clin Res* 1992;18:437-442.
71. Iarussi D, Auricchio U, Agretto A et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Mol Aspects Med* 1994;15 Suppl:s207-s212.
72. Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. *Proc Natl Acad Sci U S A* 1990;87:8931-8934.
73. Watts GF, Castelluccio C, Rice-Evans C et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. *J Clin Pathol* 1993;46:1055-1057.
74. Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. *J Clin Pharmacol* 1993;33:226-229.
75. De Pinieux G, Chariot P, Ammi-Said M et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. *Br J Clin Pharmacol* 1996;42:333-337.
76. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. *Mol Aspects Med* 1997;18 Suppl:S137-S144.
77. Silver MA, Langsjoen PH, Szabo S et al. Statin cardiomyopathy? A potential role for co-enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. *Biofactors* 2003;18:125-127.
78. Passi S, Stancato A, Aleo E et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. *Biofactors* 2003;18:113-124.
79. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10: a review of animal and human publications. *Biofactors* 2003;18:101-111.
80. Langsjoen PH, Folkers K, Lyson K et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. *Int J Tissue React* 1990;12:163-168.
81. Manzoli U, Rossi E, Littarru GP et al. Coenzyme Q10 in dilated cardiomyopathy. *Int J Tissue React* 1990;12:173-178.
82. Sinatra ST. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. *Mol Aspects Med* 1997;18 Suppl:S299-S305.
- 82a. Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. *Proc Natl Acad Sci USA* 1990 Nov;87(22):8928-8930.

Citations and Reference Literature: Copper

83. Ichihara K, Satoh K, Yamamoto A, Hoshi K. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?]. *Nippon Yakurigaku Zasshi* 1999;114 Suppl 1:142P-149P.
84. Rosenfeldt FL, Pepe S, Linnane A et al. Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. *Ann NY Acad Sci* 2002;959:355-359; discussion 463-355.
85. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. *Eur J Clin Pharmacol* 1994;46:313-317.
86. Paloma'ki A, Malminiemi K, Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. *FEBS Lett* 1997;410:254-258.
87. Paloma'ki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. *J Lipid Res* 1998;39:1430-1437.
88. Bleske BE, Willis RA, Anthony M et al. The effect of pravastatin and atorvastatin on coenzyme Q10. *Am Heart J* 2001;142:E2.
89. Rundek T, Naini A, Sacco R et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol* 2004;61:889-892.
90. Yoshida H, Ishikawa T, Ayaori M et al. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. *Clin Ther* 1995;17:379-389.
91. Baum H. *New Scientist* 1991;24. {AU: article title?}
92. Bargossi AM, Battino M, Gaddi A et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Int J Clin Lab Res* 1994;24:171-176.
93. Miyake Y, Shouzu A, Nishikawa M et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. *Arzneimittelforschung* 1999;49:324-329.
94. Pettit FH, Harper RF, Vilaythong J et al. Reversal of statin toxicity to human lymphocytes in tissue culture. *Drug Metab Drug Interact* 2003;19:151-160.
95. Watts GF, Playford DA, Croft KD et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. *Diabetologia* 2002;45:420-426.
96. Title LM, Cummings PM, Giddens K et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. *J Am Coll Cardiol* 2000;36:758-765.
97. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. *J Clin Pharmacol* 1999;39:111-118.
98. Wong B, Lumma WC, Smith AM et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. *J Leukoc Biol* 2001;69:959-962.
99. Brady AJB, Norrie J, Ford I. Statin prescribing: Is the reality meeting the expectations of primary care. *Br J Cardiol* 2005;12:397-400.
100. Goldman RE, Parker DR, Eaton CB et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. *Ann Fam Med* 2006;4:205-212.
101. Brown MS. Coenzyme Q10 with HMG-CoA reductase inhibitors. Merck and Co (Rahway, NJ); 1990.
102. Tobert JA. Coenzyme Q10 with HMG-CoA reductase inhibitors. Merck and Co (Rahway, NJ); 1990.
103. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by Adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. *Proc Natl Acad Sci U S A* 1976;73:4653-4656.
104. Singh RB, Niaz MA, Rastogi SS et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J Hum Hypertens* 1999;13:203-208.
105. Hodgson JM, Watts GF, Playford DA et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 2002;56:1137-1142.
106. Glassman AH, Roose SP. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revising risks. *Gerontology* 1994;40 Suppl 1:15-20.
107. Scahill L, Lynch KA. Tricyclic antidepressants: cardiac effects and clinical implications. *J Child Adolesc Psychiatr Nurs* 1994;7:37-39.
108. Pinto J, Huang YP, Pelliccione N, Rivlin RS. Cardiac sensitivity to the inhibitory effects of chlorpromazine, imipramine and amitriptyline upon formation of flavins. *Biochem Pharmacol* 1982;31:3495-3499.
109. Morton RA. Ubiquinones, plastoquinones and vitamins K. *Biol Rev Camb Philos Soc* 1971;46:47-96.
110. Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. *Res Commun Chem Pathol Pharmacol* 1976;13:109-114.
111. Spigset O. Reduced effect of warfarin caused by ubidecarenone. *Lancet* 1994;344:1372-1373.

Citations and Reference Literature: Copper

112. Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. *Ugeskr Laeger* 1998;160:3226-3227.
113. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. *Am J Health Syst Pharm* 2000;57:1221-1227; quiz 1228-1230.
- 113a. Engelsen J, Nielsen JD, Hansen KF. [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial] *Ugeskr Laeger*. 2003 Apr 28;165(18):1868-1871. [Danish]
114. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. *Clin Chim Acta* 2001;308:9-15.
115. Aberg F, Appelkvist EL, Broijersén A et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. *Eur J Clin Invest* 1998;28:235-242.
116. Kotake C, Ito Y, Yokoyama M, Fukuzaki H. Protective effect of coenzyme Q10 on thyrotoxic heart in rabbits. *Heart Vessels* 1987;3:84-90.
117. Mancini A, De Marinis L, Calabro F et al. Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination. *J Endocrinol Invest* 1989;12:511-516.
118. Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. *Clin Biochem* 1999;32:461-466.
119. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. *Folia Microbiol (Praha)* 1998;43:505-506.
120. Rosenfeldt FL, Mijch A, McCrystal G et al. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy. *Int J STD AIDS* 2005;16:827-829.
121. Willis R, Anthony M, Sun L et al. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. *Biofactors* 1999;9:359-363.
122. Kagan VE, Fabisak JP, Tyurina YY. Independent and concerted antioxidant functions of coenzyme Q. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton, Fla: CRC Press; 2001:119-130.
123. Thomas SR, Stocker R. Mechanisms of antioxidant action of ubiquinol-10 for low-density lipoprotein. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton, Fla: CRC Press; 2001:131-150.
61. Folkers K, Choe JY, Combs AB. Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of Adriamycin in the rat. *Proc Natl Acad Sci U S A* 1978;75:5178-5180.
62. Choe JY, Combs AB, Saji S, Folkers K. Study of the combined and separate administration of doxorubicin and coenzyme Q10 on mouse cardiac enzymes. *Res Commun Chem Pathol Pharmacol* 1979;24:595-598.
63. Choe JY, Combs AB, Folkers K. Prevention by coenzyme Q10 of the electrocardiographic changes induced by Adriamycin in rats. *Res Commun Chem Pathol Pharmacol* 1979;23:199-202.
64. Lubawy WC, Dallam RA, Hurley LH. Protection against anthracycline-induced toxicity in mice by coenzyme Q10. *J Natl Cancer Inst* 1980;64:105-109.
65. Shaeffer J, El-Mahdi AM, Nichols RK. Coenzyme Q10 and Adriamycin toxicity in mice. *Res Commun Chem Pathol Pharmacol* 1980;29:309-315.
66. Usui T, Ishikura H, Izumi Y et al. Possible prevention from the progression of cardiotoxicity in Adriamycin-treated rabbits by coenzyme Q10. *Toxicol Lett* 1982;12:75-82.
67. Shinozawa S, Kawasaki H, Gomita Y. [Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on Adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice]. *Gan To Kagaku Ryoho* 1996;23:93-98.
68. Shinozawa S, Gomita Y, Araki Y. Tissue concentration of doxorubicin (Adriamycin) in mouse pretreated with alpha-tocopherol or coenzyme Q10. *Acta Med Okayama* 1991;45:195-199.
69. Neri B, Neri GC, Bandinelli M. Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages. *Oncology* 1988;45:242-246.
70. Ronca-Testoni S, Zucchi R, Ronca F, Bertelli A. Effect of carnitine and coenzyme Q10 on the calcium uptake in heart sarcoplasmic reticulum of rats treated with anthracyclines. *Drugs Exp Clin Res* 1992;18:437-442.
71. Iarussi D, Auricchio U, Agretto A et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Mol Aspects Med* 1994;15 Suppl:s207-s212.
72. Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. *Proc Natl Acad Sci U S A* 1990;87:8931-8934.
73. Watts GF, Castelluccio C, Rice-Evans C et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. *J Clin Pathol* 1993;46:1055-1057.

Citations and Reference Literature: Copper

74. Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. *J Clin Pharmacol* 1993;33:226-229.
75. De Pinieux G, Chariot P, Ammi-Said M et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. *Br J Clin Pharmacol* 1996;42:333-337.
76. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. *Mol Aspects Med* 1997;18 Suppl:S137-S144.
77. Silver MA, Langsjoen PH, Szabo S et al. Statin cardiomyopathy? A potential role for co-enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. *Biofactors* 2003;18:125-127.
78. Passi S, Stancato A, Aleo E et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. *Biofactors* 2003;18:113-124.
79. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10: a review of animal and human publications. *Biofactors* 2003;18:101-111.
80. Langsjoen PH, Folkers K, Lyson K et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. *Int J Tissue React* 1990;12:163-168.
81. Manzoli U, Rossi E, Littarru GP et al. Coenzyme Q10 in dilated cardiomyopathy. *Int J Tissue React* 1990;12:173-178.
82. Sinatra ST. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. *Mol Aspects Med* 1997;18 Suppl:S299-S305.
- 82a. Willis RA, Folkers K, Tucker JL, et al. Lovastatin decreases coenzyme Q levels in rats. *Proc Natl Acad Sci USA* 1990 Nov;87(22):8928-8930.
83. Ichihara K, Satoh K, Yamamoto A, Hoshi K. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?]. *Nippon Yakurigaku Zasshi* 1999;114 Suppl 1:142P-149P.
84. Rosenfeldt FL, Pepe S, Linnane A et al. Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. *Ann NY Acad Sci* 2002;959:355-359; discussion 463-355.
85. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. *Eur J Clin Pharmacol* 1994;46:313-317.
86. Paloma'ki A, Malminiemi K, Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. *FEBS Lett* 1997;410:254-258.
87. Paloma'ki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. *J Lipid Res* 1998;39:1430-1437.
88. Bleske BE, Willis RA, Anthony M et al. The effect of pravastatin and atorvastatin on coenzyme Q10. *Am Heart J* 2001;142:E2.
89. Rundek T, Naini A, Sacco R et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol* 2004;61:889-892.
90. Yoshida H, Ishikawa T, Ayaori M et al. Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study. *Clin Ther* 1995;17:379-389.
91. Baum H. *New Scientist* 1991;24. {AU: article title?}
92. Bargossi AM, Battino M, Gaddi A et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Int J Clin Lab Res* 1994;24:171-176.
93. Miyake Y, Shouzu A, Nishikawa M et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. *Arzneimittelforschung* 1999;49:324-329.
94. Pettit FH, Harper RF, Vilaythong J et al. Reversal of statin toxicity to human lymphocytes in tissue culture. *Drug Metab Drug Interact* 2003;19:151-160.
95. Watts GF, Playford DA, Croft KD et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. *Diabetologia* 2002;45:420-426.
96. Title LM, Cummings PM, Giddens K et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. *J Am Coll Cardiol* 2000;36:758-765.
97. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. *J Clin Pharmacol* 1999;39:111-118.
98. Wong B, Lumma WC, Smith AM et al. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. *J Leukoc Biol* 2001;69:959-962.
99. Brady AJB, Norrie J, Ford I. Statin prescribing: Is the reality meeting the expectations of primary care. *Br J Cardiol* 2005;12:397-400.
100. Goldman RE, Parker DR, Eaton CB et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. *Ann Fam Med* 2006;4:205-212.

Citations and Reference Literature: Copper

101. Brown MS. Coenzyme Q10 with HMG-CoA reductase inhibitors. Merck and Co (Rahway, NJ); 1990.
102. Tobert JA. Coenzyme Q10 with HMG-CoA reductase inhibitors. Merck and Co (Rahway, NJ); 1990.
103. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine: prevention by forms of coenzyme Q of the inhibition by Adriamycin of coenzyme Q10-enzymes in mitochondria of the myocardium. *Proc Natl Acad Sci U S A* 1976;73:4653-4656.
104. Singh RB, Niaz MA, Rastogi SS et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J Hum Hypertens* 1999;13:203-208.
105. Hodgson JM, Watts GF, Playford DA et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. *Eur J Clin Nutr* 2002;56:1137-1142.
106. Glassman AH, Roose SP. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revising risks. *Gerontology* 1994;40 Suppl 1:15-20.
107. Scahill L, Lynch KA. Tricyclic antidepressants: cardiac effects and clinical implications. *J Child Adolesc Psychiatr Nurs* 1994;7:37-39.
108. Pinto J, Huang YP, Pelliccione N, Rivlin RS. Cardiac sensitivity to the inhibitory effects of chlorpromazine, imipramine and amitriptyline upon formation of flavins. *Biochem Pharmacol* 1982;31:3495-3499.
109. Morton RA. Ubiquinones, plastoquinones and vitamins K. *Biol Rev Camb Philos Soc* 1971;46:47-96.
110. Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. *Res Commun Chem Pathol Pharmacol* 1976;13:109-114.
111. Spigset O. Reduced effect of warfarin caused by ubidecarenone. *Lancet* 1994;344:1372-1373.
112. Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. *Ugeskr Laeger* 1998;160:3226-3227.
113. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. *Am J Health Syst Pharm* 2000;57:1221-1227; quiz 1228-1230.
- 113a. Engelsen J, Nielsen JD, Hansen KF. [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial] *Ugeskr Laeger*. 2003 Apr 28;165(18):1868-1871. [Danish]
114. Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. *Clin Chim Acta* 2001;308:9-15.
115. Aberg F, Appelkvist EL, Broijersén A et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. *Eur J Clin Invest* 1998;28:235-242.
116. Kotake C, Ito Y, Yokoyama M, Fukuzaki H. Protective effect of coenzyme Q10 on thyrotoxic heart in rabbits. *Heart Vessels* 1987;3:84-90.
117. Mancini A, De Marinis L, Calabro F et al. Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination. *J Endocrinol Invest* 1989;12:511-516.
118. Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. *Clin Biochem* 1999;32:461-466.
119. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. *Folia Microbiol (Praha)* 1998;43:505-506.
120. Rosenfeldt FL, Mijch A, McCrystal G et al. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy. *Int J STD AIDS* 2005;16:827-829.
121. Willis R, Anthony M, Sun L et al. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. *Biofactors* 1999;9:359-363.
122. Kagan VE, Fabisak JP, Tyurina YY. Independent and concerted antioxidant functions of coenzyme Q. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton, Fla: CRC Press; 2001:119-130.
123. Thomas SR, Stocker R. Mechanisms of antioxidant action of ubiquinol-10 for low-density lipoprotein. In: Kagan VE, Quinn PJ, eds. *Coenzyme Q: Molecular Mechanisms in Health and Disease*. Boca Raton, Fla: CRC Press; 2001:131-150.